Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury

Francis S. Wolenski,* 3 Andy Z. X. Zhu,* Mike Johnson,* 1 Shaoxia Yu,* Yuu Moriya,† Takuya Ebihara,† Vilmos Csizmadia,* Jessica Grieves,* Martin Paton,* Mingxiang Liao,* Christopher Gemski,* Liping Pan,‡ Majid Vakilynejad,‡ Yvonne P. Dragan,* Swapan K. Chowdhury,* and Patrick J. Kirby*,2

*Takeda Pharmaceuticals International Co, Cambridge, Massachusetts 02139; †Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan; and ‡Takeda Pharmaceuticals International Co, Deerfield, Illinois 60015

1Present address: Ignyta, 11095 Flintkote Avenue, San Diego, CA 92121
2Present address: Sanofi, 5 Mountain Road, Framingham, MA 01701
3To whom correspondence should be addressed. E-mail: francis.wolenski@takeda.com

ABSTRACT

Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects. A mechanistic investigation described in this manuscript focused on the inhibition of bile acid (BA) transporters as a driver of the liver findings. TAK-875 was an in vitro inhibitor of multiple influx (NTCP and OATPs) and efflux (BSEP and MRPs) hepatobiliary BA transporters at micromolar concentrations. Repeat dose studies determined that TAK-875 caused a dose-dependent increase in serum total BA in rats and dogs. Additionally, there were dose-dependent increases in both unconjugated and conjugated individual BAs in both species. Rats had an increase in serum markers of liver injury without correlative microscopic signs of tissue damage. Two of 6 dogs that received the highest dose of TAK-875 developed liver injury with clinical pathology changes, and by microscopic analysis had portal granulomatous inflammation with neutrophils around a crystalline deposition. The BA composition of dog bile also significantly changed in a dose-dependent manner following TAK-875 administration. At the highest dose, levels of taurocholic acid were 50% greater than in controls with a corresponding 50% decrease in taurochenodeoxycholic acid. Transporter inhibition by TAK-875 may cause liver injury in dogs through altered bile BA composition characteristics, as evidenced by crystalline deposition, likely composed of test article, in the bile duct. In conclusion, a combination of in vitro and in vivo evidence suggests that BA transporter inhibition could contribute to TAK-875-mediated liver injury in dogs.

Key words: bile acid inhibition; biliary excretion; drug induced liver injury; biomarkers.

Fasiglifam (TAK-875) is a small molecule agonist of the Free Fatty Acid Receptor 1 (FFAR1), which is also known as G-protein-coupled receptor 40 (GPR40) (Negoro et al., 2010), that was developed for the treatment of type 2 diabetes (Burant et al., 2012; Leifke et al., 2012; Naik et al., 2012). Clinical data indicated that there was a benefit for patients who received TAK-875 based on improved glycemic parameters (Kaku et al., 2013). However, the development activities of TAK-875 were...
voluntarily terminated in 2013 due to liver safety concerns (Kaku et al., 2015, 2016). This outcome presented an opportunity to investigate potential mechanisms of the toxicity with animal models. The hypothesis tested in the nonclinical studies was that TAK-875 alters bile acid (BA) homeostasis, which may be a contributing factor to drug induced liver injury (DILI).

Bile is comprised of a combination of bile acids (BAs), phospholipids (such as phosphatidylcholine), protein, cholesterol, fatty acid, and conjugated bilirubin (Farina et al., 2009; Nicolaou et al., 2012). BAs are synthesized from cholesterol in the liver through a series of enzymatic steps (Russell, 2003). The primary bile acids in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA) (Zhang et al., 2011). These 2 BAs undergo extensive modification that includes conjugation (with either taurine or glycine), reduction, dehydrogenation, oxidation, and cleavage to create a diverse BA pool (Chiang, 2013). In humans, most BAs in bile are conjugated to glycine (Monte et al., 2009). BAs are exported from the liver into the bile and then secreted into the intestinal tract to aid in nutrient absorption (Chiang, 2009). As a part of enterohepatic circulation, BAs are reabsorbed in the ileum of the small intestine, enter the bloodstream, and return to the liver (Hofmann, 2009). Some BAs are modified by bacterial enzymes in the intestine, which alters their rate of elimination or reabsorption (Bidlon et al., 2006). In humans, this enterohepatic circulation loop runs 4–12 times a day and can recycle 95% of BAs (Chiang, 2013).

Movement into and out of hepatocytes is largely mediated by specific transport proteins because most BAs cannot undergo passive diffusion due to their ionic charges (Dawson et al., 2009). Detailed mechanisms of BA transport are extensively reviewed elsewhere (Alrefai and Gill, 2007; Chiang, 2013; Rodrigues et al., 2014). Briefly, BA uptake into hepatocytes is mediated by Na+-taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs), while export is mediated by the bile salt export pump (BSEP) and multidrug resistance-associated proteins (MRPs) (Hallibasic et al., 2013). Both BSEP and MRFP2 export BAs to the bile canaliculus while MRP3 and MRP4 transport to the blood (Morgan et al., 2010; Yang et al., 2013). Unconjugated BAs can act as detergents that can cause liver injury if their concentration gets too high (Monte et al., 2009). One protective mechanism is to conjugate the BAs to glycine or taurine in the liver as a means to promote canalicular transport (Attili et al., 1986). There are other transporters, such as apical sodium-dependent bile salt transporter (ASBT) and organic solute transporter (OST)γ/β, that also have a role in hepatic bile acid transport (Yang et al., 2013).

Mutations of the human BSEP gene can lead to progressive hepatic cholestasis (Noe et al., 2005; Stieger et al., 2007) and increase the susceptibility to drug-induced cholestasis (Lang et al., 2007). BSEP knockout mice develop a mild form of cholestasis (Wang et al., 2001) but other transporters are able to compensate and mitigate the severity of the disease (Lam et al., 2005; Wang et al., 2009). Chemicals that inhibit BSEP can cause cholestatic injury (Dawson et al., 2012). From a broader perspective, inhibition of BA transporter activity appears to be a contributing factor to DILI (Aleo et al., 2014; Fattinger et al., 2001; Kostrubsky et al., 2006). One recent model has established a link between the level of BSEP inhibition and the clinical exposure to predict whether the drug could cause DILI (Morgan et al., 2013).

Initial in vitro evidence that TAK-875 could inhibit multiple BA transporters prompted a more thorough mechanistic investigation. The results of this study describe nonclinical in vitro and in vivo findings about the effects of TAK-875 on BA homeostasis in animals. We hypothesized that TAK-875 inhibition of BA transporters may be a contributing factor to drug-induced liver effects in animals. Both TAK-875 and the primary glucuronide metabolite TAK-875-Glu were in vitro inhibitors of multiple BA transporters. Rats and dogs administered TAK-875 daily for 2 weeks had dose-dependent increases in the level of serum BAs. Additionally, the BA composition of dog bile was also significantly altered by TAK-875. This work demonstrates that TAK-875-mediated transporter inhibition alters BA homeostasis in animals, which in turn may be a contributing factor to DILI.

**MATERIALS AND METHODS**

**Materials**

TAK-875 and TAK-875-Glu were synthesized internally at Takeda Pharmaceuticals.

**Cell Based Assays**

Single donor cryopreserved human hepatocytes (lot HH1031) were obtained from In Vitro ADMET Laboratories (IVAL; Columbia, MD). Cells were thawed in UCRM media (IVAL) and plated in HQM media (IVAL) at 25,000 cells/well in collagen coated, clear-bottom 96-well plates and incubated overnight at 37 °C with 5% CO₂. Four hours after plating, the media was replaced with HQM that contained 0.1% DMSO or test compounds dissolved in DMSO. Duplicate cell cultures were treated with 0.1–100 μM of TAK-875 or TAK-875-Glu. For cell viability assays, the CellTiter-Glo kit (Promega, Madison, WI, USA) was used to measure intracellular ATP after 6 or 24 h of incubation with the test compound. For glutathione quantification assays, the GSH-Glo kit (Promega) was used after 6 h of incubation. For both assays, luminescence was quantified using a Victor3 V Plate Reader (Perkin-Elmer, Waltham, MA). Data were analyzed in Prism 5 (Graphpad Software, La Jolla, CA), and the least-squares method was used to determine the concentration causing lethality for 50% of cells (LC₅₀).

A Seahorse XFe96 Analyzer (Seahorse Bioscience, North Billerica, MA) was used to measure the mitochondrial effects of TAK-875 and TAK-875-Glu on hepatocytes. Cryopreserved primary human hepatocytes from a single donor were thawed and cultured on XF 96-well cell culture microplates (Seahorse Biosciences) in triplicate. The oxidative phosphorylation and glycolysis stress test media (Seahorse Biosciences) were prepared following manufacturer’s instructions using protein-free media. Cells were maintained in a CO₂-free incubator for 1 h at 37 °C prior to measuring the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 3 times over a 28 min span to establish a baseline. Compounds were added and the OCR and ECAR were measured in triplicate samples over a 42 min period. Data was analyzed with the XF Wave (v 2.3) software (Seahorse Bioscience). Results for the final measurement were normalized as a percentage of DMSO control wells.

For the glucose and galactose (Gluc-Gal) assay, HepG2 human hepatocellular carcinoma cells were plated on a 96-well cell culture microplate in DMEM (ThermoFisher Scientific, Cambridge, MA) supplemented with 10% fetal bovine serum (ThermoFisher Scientific) and cultured overnight. The next day, the medium was replaced with medium containing 25 mM glucose or 10 mM galactose. Cells were dosed in triplicate with either vehicle (0.5% DMSO) or a range of TAK-875 or TAK-875-Glu concentrations (in 0.5% DMSO) and incubated for 72 h at 37 °C. Cells were stained with Hoechst 33342 (Life Technologies, Carlsbad, CA) and viability was determined with an automated
fluorescent cellular imager, ArrayScan VTI (ThermoFisher Scientific).

Transporter Assays
For transporters assay, membrane vesicles prepared from baculovirus-infected S9 insect cells that over expressed human transporters were purchased from GenoMembrane, Inc. (Yokohama, Japan). These included vesicles for BSEP (GM0005), MRPs (GM0001, GM0021), and MRP4 (GM0012). HEK293 cells transfected with vectors containing OATP1B1 or OATP1B3 were obtained from ADME & Tox. Research Institute (Sekisui Medical Co., Tokyo, Japan). Radiolabeled substrates for the BSEP and NTCP assay ([³H]-taurocholate) and for the MRP2, MRP3, MRP4, OATP1B1, and OATP1B3 assays ([³H]estradiol-17β-glucuronide) were purchased from PerkinElmer Life and Analytical Sciences (Waltham, Massachusetts). For the NTCP assay, the radio-labeled substrate ([³H]-taurocholate) was purchased from American Radiolabeled Chemicals (St. Louis, MO).

The BSEP and MRP2/3/4 assays were performed as described elsewhere (van Staden et al., 2012). Reaction incubation times were the following: BSEP, 1 min; MRP2, 2 min; MRP3, 15 min; MRP4, 15 min. Radioactivity was measured with a Tri-Carb 3100TR liquid scintillation counter (PerkinElmer) for the BSEP and MRP2 assays, and with a MicroBeta² 2450 (PerkinElmer) for MRP3 and MRP4 assays. The OATP1B1 and OATP1B3 assays were performed as described elsewhere (Oshida et al., 2016). The reactions were terminated after 2 min, cells were washed in PBS, lysed with 0.1 M sodium hydroxide, and the radioactivity measured with a Hionic-Fluor scintillator (PerkinElmer). The NTCP assay was performed essentially as described (Swift et al., 2010). Cryopreserved primary human hepatocytes were obtained from IVAL and were plated at 200,000 cells/well on a 48-well plate following manufacturer's instructions. Three hours after plating the cells were washed twice with Hanks' Balanced Salts solution (HBSS) media (ThermoFisher Scientific) and incubated in HBSS media. Sodium-free buffer was used as a negative control. Uptake was initiated by adding HBSS containing 100 nM [³H]taurocholic acid in the absence or presence of multiple concentrations of TAK-875 or TAK-875-Glu. The assays were terminated after a 2 min incubation. The cells washed and lysed with 0.5% Triton X-100, and the radioactivity of cell lysates was assessed with a MicroBeta² 2450 detector.

Rat Studies
Ten-week-old male Sprague Dawley rats were purchased from Charles River Laboratories (Charlestown, SC) and acclimated to their surroundings for 13 days. The environmental conditions of the animal facility were: a 12:12 h light:dark cycle; a temperature of 18–29°C; a relative humidity of 50 ± 20%; and ventilation changes of ≥10 per hour. Animals were supplied with PMI Nutrition International Certified Canine Chow (Lab Diet® #5002, PMI Nutrition International LLC) and ad libitum with reverse osmosis-filtered water. The food ration was offered up to 2 h after dosing, and as an exception, animals were fed following the 6-h blood collection time point on Days 1, 7, and 14, and then fasted overnight prior to the 24-h time point. Six dogs each received a 5 ml/kg oral gavage of vehicle (0.5% methylcellulose), 40, 150, or 600 mg/kg TAK-875 for 14 consecutive days. Whole blood was collected from every animal at predose, 1, 3, and 24 h after doses on days 1, 7, and 14 via venipuncture of the jugular vein. Whole blood was processed using the method described for rats. Serum samples were analyzed with an Olympus AU640e Chemistry Immuno Analyzer (Olympus) by Charles River Laboratories (Spencerville, OH). Bile was collected from the gall bladder at scheduled euthanasia. Liver samples were processed as described for rats. Euthanasia consisted of an injection with sodium pentobarbital followed by exsanguination. One dog that received 150 mg/kg TAK-875 underwent unscheduled euthanasia on day 8 for humane reasons due to a dose administration error. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals. All animal experiments for this study were conducted in accordance with Charles River Laboratories’ Institutional Animal Care and Use Committee Guidelines.

Toxicokinetic Analysis
The concentration of TAK-875 in the plasma samples was determined using a qualified liquid chromatography with tandem mass spectrometry (LC/MS/MS) method. A protein precipitation extraction method was used for sample preparation. Briefly, a Sciex API-4000 mass spectrometer (AB Sciex, Concord, Ontario,
Canada) equipped with a Agilent 1200 LC System (Agilent Technologies, Santa Clara, CA) and a LEAP autosampler (LEAP Technologies, Carrboro, NC) used a reverse-phase gradient method running on an ACE C18 column (2.0 mm ID 2.0 x 50 mm; particle size 3 μm, [Advanced Chromatography Technologies, Aberdeen, Scotland]) for the analyte separation. The mobile phases used were in (A) 95:5 (v:v) water:acetonitrile and (B) 50:50 (v:v) methanol:acetonitrile, and both were supplemented with formic acid (0.1%, volume-to-volume ratio [v:v]). TAK-875 was ionized under a positive ion spray mode and detected through the multiple-reaction monitoring of a mass transition pair at a mass-to-charge ratio (m/z) of 525.6/465.2. Calibration curves of TAK-875 were established using standards, and the peak area ratios of the analyte against the internal standard (glyburide; Sigma-Aldrich, St. Louis, MO) were used to quantify samples. Toxicokinetic analysis of the individual plasma concentration

FIG. 1. TAK-875 and the primary metabolite TAK-875-Glu were evaluated in cell-based assays. A, The structures of TAK-875 and its primary metabolite TAK-875-Glu. B–D, Primary human hepatocytes were treated with the indicated concentrations of TAK-875 (box with solid line) or TAK-875-Glu (triangle with dashed line). Values are normalized to appropriate DMSO controls. B, Cells were treated with compounds for either 6 (left) or 24 (right) hours and survival was determined by intracellular ATP quantification. C, A Seahorse XFe96 Analyzer was used to assess mitochondrial effects of the indicated compounds on oxygen consumption (left) and extracellular acidification of the media (right). D, Levels of glutathione (GSH) after a 6 h incubation with compounds. E, Human HepG2 cells were incubated in media that contains glucose (Gluc) or galactose (Gal) as the only energy source. A nonlinear fit of the data was used to determine the LC50. Error bars indicate standard error of the mean.
data was performed using Phoenix WinNonlin, v.6.3 (Pharsight Corp, Mountain View, CA). Kinetic parameters were estimated using a noncompartmental model. The area under the curve during 24 h (AUC0–24) was calculated using the linear trapezoidal rule.

Individual Bile Acid Analysis
The concentration of individual BAs in serum samples was determined by LC/MS/MS. Samples were prepared by extracting a 50 μl aliquot of serum with 200 μl acetonitrile containing 0.1% formic acid. The sources of the standards for the 21 different BAs are included in the Supplementary Information. BAs are either unconjugated, taurine (T)-conjugated, or glycine (G)-conjugated. The following BAs were measured: unconjugated BAs: UDCA, ursodeoxycholic acid; HDCA, hyodeoxycholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; CA, cholic acid; aMCA, alpha-muricholic acid; bMCA, beta-muricholic acid; LCA, lithocholic acid; T-conjugated BAs: TCA, taurodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; THDCA, taurohyodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; TLCA, tauro lithocholic acid; TCA, taurocholic acid; TaMCA, tauro-alpha-muricholic acid; TbMCA, tauro-beta-muricholic acid; and G-conjugated BAs: GCA, glycocholic acid; GDCA, glycodeoxycholic acid; GCDCA, glycodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; GLCA, glycolithocholic acid.

For LC/MS/MS, an Eksigent MicroLC 200 system equipped with a QTRAP 5500 (AB Sciex) mass spectrometer and a LEAP autosampler running on a ACQUITY UPLC BEH C18 column (1.0 mm ID 2.1 × 50 mm; particle size 1.7 μm [Waters Corporation, Milford, MA]) at a flow rate of 50 μL/min for the analyte separation. The mobile phases used were (A) 25 mM ammonium acetate (pH 4) and (B) 10 mM ammonium acetate in 90:10 (v:v) water:acetonitrile. The LC gradient used in this study is as follows (time [minutes], %B): 0, 32%; 1.6, 32%; 1.62, 38%; 6, 45%; 9, 45%; 13, 90%; 15.1, 90%. The gradient condition then returned to 32% B for equilibration. Internal standards using individual BAs were added before the precipitation. Calibration curves of BAs were established using standards for each analyte, and the peak area ratios of the analyte to internal standard were used to quantify samples.

Statistical Analyses
Two different types of statistical analyses were utilized that depended on the type of data analyzed. First, comparisons were made between the means of treatment versus control groups with student t-tests (unpaired and 2-tailed). Second, the relationship between TAK-875 plasma concentrations and serum total BA concentrations in rats and dogs were assessed using Pearson’s correlations. Statistical analyses were performed with GraphPad Prism (v6.07; GraphPad Software, La Jolla CA).
RESULTS

The pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of TAK-875 were established in rats and dogs before the compound entered the clinic (Negoro et al., 2010). Glucuronidation to TAK-875-Glu (Figure 1a) is the primary elimination pathway of TAK-875 in rats, dogs and humans (manuscript in preparation). Therefore, both TAK-875 and TAK-875-Glu were characterized in cell-based assays to identify potential toxicities. Primary human hepatocytes were treated with a range of compound concentrations (0.1–100 μM) that bracketed the 4.4 μM maximal plasma concentration (C_max) of a single 50-mg dose in humans (Mayer et al., 2014). Cells tolerated ≤25 μM of either compound at 6 and 24 h of treatment (Figure 1b). The mitochondrial effects of the compounds were assessed with a Seahorse XF96 Analyzer. There were no effects on oxygen consumption or extracellular acidification at compound concentrations ≤20 μM (Figure 1c). Additionally, there was no evidence of glutathione depletion (Figure 1d) or production of reactive oxygen species (Supplementary Figure 1) that was indicative of reactive oxygen stress. Human HepG2 cells were then used to determine whether there were effects on glycolysis or mitochondrial oxidative phosphorylation by growing cells in media that contained either glucose (Gluc) or galactose (Gal) as an energy source (Marroquin et al., 2007). The half maximal lethal concentration (LC_{50}) was determined for cells treated with either TAK-875 or TAK-875-Glu (Figure 1e). The Gluc/Gal ratio was essentially the same between culture conditions, which was below the 2.0 threshold considered for a positive result (Swiss et al., 2013).

The maintenance of BA homeostasis is a complicated process that involves numerous BA transport proteins (Chiang, 2013; Rodrigues et al., 2014). A schematic diagram of the principal influx (NTCP, OATPs) and efflux (BSEP, MRPs) transporters is shown in Figure 2a. Influx transporters include NTCP, OATP1B1 and OATP1B3, and efflux transporters include BSEP, MRP2, MRP3, and MRP4. The ability of TAK-875 and TAK-875-Glu to inhibit the human version of these transporters was evaluated in vitro and the corresponding half maximal inhibitory concentration (IC_{50}) values were determined (Figure 2b). Both compounds inhibited human BSEP activity in a membrane vesicle assay (Figure 2c). Interestingly, TAK-875 stimulated then inhibited human MRP2 activity, while TAK-875-Glu was only inhibitory at the concentrations tested (Figure 2d). Taken together, both TAK-875 and TAK-875-Glu were inhibitors of multiple BA transporters at low micromolar concentrations.

Animal studies were conducted to determine whether there was an actual in vivo relationship between the transporter assay data and effects on BAs in vivo. Rats received daily oral administration of 0, 200, or 600 mg/kg TAK-875 for 14 days. Fasted blood was collected on days 1, 7, and 14 for biomarker and PK analysis. The time of maximal plasma concentration (T_{max}) for TAK-875 occurred at 6 h postdose for all groups and days (Supplementary Table 1). There were significant effects on total BA (TBA) levels within 3 h of TAK-875 dosing (Figure 3a). For the 600 mg/kg group, levels of TBA remained elevated throughout
the 14 day study, even in samples collected 24 h after the previous dose. The serum levels of 2 biomarkers of liver injury, bilirubin (Figure 3b) and alanine aminotransferase (ALT) (Figure 3c), were elevated in the 600 mg/kg-dosed animals after the first week. However, other serum markers of liver damage remained at baseline (Supplementary Table 2) and there was no correlative microscopic evidence of liver injury (data not shown). Additionally, there was no significant change in the amount of TBA in the feces of rats that received TAK-875 for 2 weeks (Supplementary Figure 2), or in the livers of rats that received 2 doses of TAK-875 (Supplementary Figure 3). Taken together, TAK-875 clearly affected the serum BA levels in rats but
the ALT elevation was asymptomatic as there was no clear evidence of liver damage. The complete raw dataset for rats is presented in Supplementary Table 3.

Dogs received daily oral administration of 0, 40, 150, and 600 mg/kg TAK-875 for 14 days. The TAK-875 T\text{max} was approximately 1−3 h postdose (Supplementary Table 4). Two of the 6 dogs at the 600 mg/kg level developed liver injury between day 7 and 14. The damage was characterized by granulomatous inflammation with neutrophils around an intralesional crystal-line deposition (Figure 4a, white arrows). Biliary hyperplasia and fibroplasia were also present. Crystal formation within areas of granulomatous inflammation (black arrows) can be seen in both dogs “S” (Figure 4b) and “U” (Figure 4c). Similar crystal depositions collected from a previous dog study were identified by LC/MS as precipitated TAK-875 and its metabolite TAK-875-Glu (manuscript in preparation). No other dog had TAK-875-related microscopic changes. On day 14, the 2 dogs with liver injury had the highest serum levels of TBA, ALT, and bilirubin measured over the course of the study (Figure 4d). The mean serum TBAs are shown for groups 0, 40, 200, 600 (dogs T, V, W and X), and 600 mg/kg (dogs S and U) to illustrate the magnitude of changes (Figure 4e). Changes in other serum markers of liver damage are shown in (Supplementary Table 5), and the complete data set is presented in Supplementary Table 6.

The PK/PD relationship between the plasma concentration of TAK-875 and serum TBA was then assessed in both species. This analysis combined every time-matched plasma and serum sample across all dose groups. Measurements from vehicle-dosed animals were included to account for the natural variation of BA levels. A Pearson correlation coefficient analysis was conducted to determine the statistical significance (P) and the correlation coefficient (r) of the relationship. There was a strong correlation between TAK-875 concentrations and TBA levels for rats (Figure 5a; r = 0.77, P < .0001) and dogs (Figure 5b; r = 0.51, P < .0001). Thus, higher concentrations of TAK-875 are associated with increased levels of TBA in both animal species.

Rat and dog serum samples were then analyzed by LC/MS/MS for 21 different BAs. This extensive data set is included as time-matched samples for both rats (Supplementary Table 3) and dogs (Supplementary Table 4). Analysis of the data revealed that the levels of many BAs changed in relation to the TAK-875 dose (Supplementary Figs. 4–9). At the end of the rat study, there was a significant 8-fold increase of CA in 600 mg/kg TAK-875 group versus control animals (Figure 6a). In dogs, there was a significant 250-fold increase in TCA in the two 600 mg/kg dogs with liver injury versus controls (Figure 6b), and a 7-fold increase versus the 600 mg/kg no-injury group. Bile was also collected from dogs and analyzed for individual BAs. Three BAs (TCA, TDCA and TCDCA) comprise 95% of BA in dog bile (Figure 6c). Interestingly, TAK-875 caused a significant increase in the proportion of TCA (upper line) in the bile that corresponded to a decrease in TDCA (lower line). The percentages of TCA and TDCA for the 2 dogs with liver injury, S and U, are labeled. By a Pearson correlation coefficient analysis, these dose-dependent trends were significant for both TCA (P < .0028) and for TDCA (P < .014). When these bile BA data are alternatively analyzed by dose, the 600 mg/kg group has 2.4-fold more TCA than TDCA (Supplementary Table 7). Taken together, TAK-875 has clear BA effects on serum levels in rats and dogs, and in the bile of dogs.

**DISCUSSION**

The definitive cause for the liver effects seen in the TAK-875 clinical program remains unknown. Two of 6 dogs that received 600 mg/kg developed a liver injury that was characterized by crystalline deposition in the biliary duct with biliary hyperplasia and fibroplasia. In comparison, rats had an asymptomatic increase in serum ALT but no correlative microscopic evidence of liver damage. The key common finding between both species was a TAK-875 effect on the level of serum BAs.

Bile acid (BA) transporter inhibition can be identified by elevated serum BAs (Rodrigues et al., 2014). There was a clear relationship between TAK-875 plasma concentrations and serum TBA levels in both the rat (Figure 5a) and dog (Figure 5b). The first dose of 600 mg/kg TAK-875 caused a 5-fold increase of TBA in rats (Figure 3a) and an approximately 10-fold increase in dogs (Figure 4e) within a few hours of administration. TAK-875 and TAK-875-Glu inhibit multiple human BA transporters at similar low micromolar concentrations (Figure 2a). Similarly, TAK-875 was shown to be an inhibitor of multiple rat hepatobiliary transporters (Li et al., 2015). Taken together, the effects on...
TAK-875 caused changes in the levels of individual BAs from rats and dogs. Serum or bile was collected from animals at the indicated time points and the levels of 21 individual bile acids were determined using LC/MS/MS. A–B, Bile acids are grouped by type of modification (unconjugated, taurine [T]-conjugated, or glycine [G]-conjugated). The doses and groups are displayed to the right of graphs. Asterisks indicate a statistically significant ($P < .05$) difference in the means of treatment groups versus the control group. A, Rat serum was collected 24 h after the day 14 dose. B, Dog serum collected 6 h after the day 14 dose. The 600 mg/kg dose group was further divided into the 4 dogs without liver damage (no injury) and the 2 dogs with the liver damage (injury). C, Dog bile collected from animals 24 h after the day 14 dose. The proportion of each BA within the total BA pool was normalized for each animal. Plasma TK data was used to determine the day 14 exposure. The percentage of TCA, TDCA, and TCDCA are as shown; the remaining 18 BAs were combined into one value (All Others). A linear regression line was generated by minimizing the sum of squares. The dotted line shows a 95% confidence interval. A Pearson’s correlation coefficient analysis was conducted to determine the statistical significance ($P$) and the correlation coefficient ($r$). Only statistically significant relationships ($P < .05$) are shown. The TCA and TDCA data points for dogs “S” and “U” are labeled.

FIG. 6. TAK-875 caused changes in the levels of individual BAs from rats and dogs. Serum or bile was collected from animals at the indicated time points and the levels of 21 individual bile acids were determined using LC/MS/MS. A–B, Bile acids are grouped by type of modification (unconjugated, taurine [T]-conjugated, or glycine [G]-conjugated). The doses and groups are displayed to the right of graphs. Asterisks indicate a statistically significant ($P < .05$) difference in the means of treatment groups versus the control group. A, Rat serum was collected 24 h after the day 14 dose. B, Dog serum collected 6 h after the day 14 dose. The 600 mg/kg dose group was further divided into the 4 dogs without liver damage (no injury) and the 2 dogs with the liver damage (injury). C, Dog bile collected from animals 24 h after the day 14 dose. The proportion of each BA within the total BA pool was normalized for each animal. Plasma TK data was used to determine the day 14 exposure. The percentage of TCA, TDCA, and TCDCA are as shown; the remaining 18 BAs were combined into one value (All Others). A linear regression line was generated by minimizing the sum of squares. The dotted line shows a 95% confidence interval. A Pearson’s correlation coefficient analysis was conducted to determine the statistical significance ($P$) and the correlation coefficient ($r$). Only statistically significant relationships ($P < .05$) are shown. The TCA and TDCA data points for dogs “S” and “U” are labeled.
serum TBA appear to be a direct result of BA transporter inhibition. Repeated administration of 600 mg/kg TAK-875 caused crystalline depositions in the biliary tract of 2 dogs. The elevation of the serum markers of cholestasis, ALP and GGT, are consistent with this type of injury. Crystallization of TAK-875 and its primary metabolite TAK-875-Glu was also observed in 9-month repeat dose studies in dogs with 150 mg/kg TAK-875 (data not shown). Yet in rats, crystal formation was not observed in a 6-month rat study at doses up to 200 mg/kg (data not shown). In bile duct-cannulated studies, a single dose of 200 mg/kg TAK-875 did not impair bile flow in either rats or dogs (data not shown). Key biological and physiological differences between the species may explain the discrepancy. First, the rate of bile flow (normalized against body weights) is approximately 7-fold higher in rats than dogs (Davies and Morris, 1993). Second, while rats and dogs predominantly have taurine-conjugated BAs, their respective BA pools have different compositions (Suzuki et al., 2013; Washizu et al., 1990). And finally, rats naturally have very high levels of BSEP activity (Jennitz et al., 2010) that may have made them less susceptible to TAK-875-mediated transporter inhibition. These and/or other potentially unknown factors may explain why the rat tolerated high doses of TAK-875 while dogs did not.

The mechanism behind the dramatic change in the bile BA composition of dogs administered TAK-875 is unknown. Both TCA and TDCA were at equal proportions in vehicle-dosed animals, but TAK-875 caused an increase in TCA with a corresponding decrease in TDCA (Figure 6c). Both TCA and TDCA are transported by BSEP, intestinal bacteria convert TCA to TDCA, and they are then reabsorbed in the gut as part of enterohepatic circulation (Kosters and Karpen, 2008; Legido-Quigley et al., 2011). The 2 dogs with liver injury had 2.5-fold more TCA than TDCA, but so did other dogs without injury (Supplementary Table 7), which suggests this is not the case of TCA accumulating at toxic levels. Unfortunately, bile was not analyzed for other parameters such as fatty acids, protein or bilirubin that could have provided insight into how the compound affected the bile. Future studies could also utilize bile duct cannulation to characterize the TAK-875 effects on bile using samples collected around the known plasma Cmax.

A recent model related to the plasma steady state concentration (Css) of a drug and its inhibition of BSEP to liver injury has been reported (Morgan et al., 2013). This approach concluded that compounds with a low BSEP IC50 and a high Css/BSEP IC50 ratio are at a higher risk for DILI (Morgan et al., 2013). The Cmax was 7.7 μM for a 50 mg dose of TAK-875 (Leifke et al., 2012), and the in vitro BSEP IC50 was 14.3 μM (Figure 2b). This Cmax/BSEP IC50 ratio of 0.53 puts TAK-875 in the high risk zone using the Morgan et al. classification system. TAK-875 also stimulated MRP2 activity (Figure 2d). This is interesting given that multiple compounds that caused DILI were similarly found to be both BSEP inhibitors and MRP2 stimulators (Morgan et al., 2013). Screening of compounds for the inhibition/stimulation effects on BA transporters may be a useful first step in de-risking future programs.

Translating animal findings from nonclinical studies to human outcomes is extraordinarily difficult. One drawback of the TAK-875 hepatobiliary transporter hypothesis was much of the significant serum BA changes required doses of 600 mg/kg. For example, dogs had a TAK-875 plasma AUC(0-24) of 3800 μg·h/ml after 14 days of dosing at this concentration (Supplementary Table 4). Humans were administered TAK-875 (fasiglifam) at 25 and 50 mg in phase 3 clinical trials that were ultimately discontinued due to concerns about liver safety (Kaku et al., 2015, 2016). By comparison of exposures, the 600 mg/kg dogs had an exposure approximately 40- to 100-fold greater than humans who received repeat doses of 25 or 50 mg TAK-875 (AUC(0-24) of 40.3 and 100.3 μg·h/ml, respectively) (Leifke et al., 2012). Unfortunately, there is no published information about BA levels in humans who received TAK-875. In conclusion, while TAK-875 BA transporter inhibition may have contributed to the liver injury of dogs, it is unclear whether these effects are relevant to humans at the clinical therapeutic doses.

**SUPPLEMENTARY DATA**

Supplementary data are available at Toxicological Sciences online.

**ACKNOWLEDGMENTS**

We thank Rachel Peters, Shylah Wyllie, Danielle Markham, Adam Brown, Russ Naven, and Johnny Yang for experimental help and analysis; John Marcink, Neila Smith, Mitchell Friedman, Christopher Northey, Prabhakar Viswanathan, Gail Cruz, Cindy Xia, Sean Ottinger, and Juliana Oliveira for protocol design and helpful discussions; Cyprotex (Watertown, MA) for high content screening work; and IVAL for hepatocyte assay development.

**FUNDING**

All authors were compensated employees of Takeda Pharmaceutical Company Limited when this research was conducted.

**REFERENCES**

Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., and Will, Y. (2014). Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60, 1015–1022.

Alrefai, W. A., and Gill, R. K. (2007). Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm. Res. 24, 1803–1823.

Attili, A. F., Angelico, M., Cantafiora, A., Alvaro, D., and Capocaccia, L. (1986). Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids. Med. Hypotheses 19, 57–69.

Buurant, C. F., Viswanathan, P., Marcink, J., Cao, C., Vakilynejad, M., Xie, B., and Leifke, E. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403–1411.

Chiang, J. Y. (2009). Bile acids: Regulation of synthesis. J. Lipid Res. 50, 1955–1966.

Chiang, J. Y. (2013). Bile acid metabolism and signaling. Compr. Physiol. 3, 1191–1212.

Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095.

Dawson, P. A., Lan, T., and Rao, A. (2009). Bile acid transporters. J. Lipid Res. 50, 2340–2357.

Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012). In vivo inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130–138.
Farina, A., Dumonceau, J. M., and Lescuyer, P. (2009). Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev. Proteomics 6, 285–301.

Fattinger, K., Funk, C., Fantz, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223–231.

Hailbasic, E., Claudel, T., and Trauner, M. (2013). Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155–168.

Hofmann, A. F. (2009). The enterohepatic circulation of bile acids and the multidrug resistance protein 3 associated with drug-porters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155–168.

Jemmitz, K., Veres, Z., and Verczeczy, L. (2010). Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol. Sci. 115, 80–88.

Kaku, K., Araki, T., and Yoshinaka, R. (2013). Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36, 245–250.

Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2015). Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 17, 675–681.

Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2016). Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: A 52-week open-label phase III study. Diabetes Obes. Metab. 18, 925–929.

Kosters, A., and Karpen, S. J. (2008). Bile acid transporters in health and disease. Xenobiotica 38, 1043–1071.

Kostrubsky, S. E., Strom, S. C., Kalugtkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451–459.

Lam, P., Wang, R., and Ling, V. (2005). Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 44, 12598–12605.

Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., Kullak-Ublick, G. A., Meier, P. J., and Pauli-Magnus, C. (2007). Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genom. 17, 47–60.

Legido-Quigley, C., McDermott, L., Vilca-Melendez, H., Murphy, G. M., Heaton, N., Lindon, J. C., Nicholson, J. K., and Holmes, E. (2011). Bile UPLC-MS fingerprinting and bile acid fluxes during human liver transplantation. Electrophoresis 32, 2063–2070.

Leifke, E., Naik, H., Wu, J., Viswanathan, P., Demanno, D., Kipnes, Y., and Vaklynejad, M. (2012). A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Ther. 92, 29–39.

Li, X., Zhong, K., Guo, Z., Zhong, D., and Chen, X. (2015). Fasiglifam (TAK-875) inhibits hepatobiliary transporters: A possible factor contributing to fasiglifam-induced liver injury. Drug Metab. Dispos. 43, 1751–1759.

Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., and Will, Y. (2007). Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539–547.

Mayer, M., Nudurupati, S., Peng, X., and Marcinka, J. (2014). Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function. Drugs R D 14, 273–282.

Monte, M. J., Marin, J. J., Antelo, A., and Vazquez-Tato, J. (2009). Bile acids: Chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804–816.

Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachadrann, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., and Hamdeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485–500.

Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kallonzi, J., Dunn, R. T., 2nd, Afshari, C. A., and Hamadeh, H. K. (2013). A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 136, 216–241.

Naik, H., Vaklynejad, M., Wu, J., Viswanathan, P., Dote, N., Higuchi, T., and Leifke, E. (2012). Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J. Clin. Pharmacol. 52, 1007–1016.

Negoro, N., Sasaki, S., Mikami, S., Ito, M., Suzuki, M., Tsujihata, Y., Ito, R., Harada, A., Takeuchi, K., Suzuki, N., et al. (2010). Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1, 290–294.

Nicolaou, M., Andress, E., Zolnericks, J. K., Dixon, P. H., Williamson, C., and Linton, K. J. (2012). Canalicular ABC transporters and liver disease. J. Pathol. 226, 300–315.

Noe, J., Kullak-Ublick, G. A., Jochum, W., Stieger, B., Kerb, R., Habeli, M., Mullhaupt, B., Meier, P. J., and Pauli-Magnus, C. (2005). Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J. Hepatol. 43, 536–543.

Oshida, K., Shimamura, M., Seya, K., Ando, A., and Miyamoto, Y. (2016). Identification of transporters involved in beraprost sodium transport in vitro. Eur. J. Drug. Metab. Pharmacokinet. doi: 10.1007/s13318-016-0327-4.

Ridlon, J. M., Kang, D. J., and Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259.

Rodriguez, A. D., Lai, Y., Cvijic, M. E., Elkin, L. L., Zvyaga, T., and Soars, M. G. (2014). Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: Mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab. Dispos. 42, 566–574.

Russell, D. W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174.

Stieger, B., Meier, Y., and Meier, P. J. (2007). The bile salt export pump. Pflugers Arch. 453, 611–620.

Suzuki, Y., Kaneko, R., Nomura, M., Naito, H., Kitamori, K., Nakajima, T., Ogawa, T., Hattori, H., Seno, H., and Ishii, A. (2013). Simple and rapid quantitation of 21 bile acids in rat bile acid synthesis. Annu. Rev. Biochem. 72, 137–174.

Swift, B., Pfeifer, N. D., and Brouwer, K. L. (2010). Sandwich-culture of rat bile acids. doi: 10.1007/s13318-016-0327-4.

Toxicological SCIENCES, 2017, Vol. 157, No. 1
Swiss, R., Niles, A., Cali, J. J., Nadanaciva, S., and Will, Y. (2013). Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death. Toxicol. In Vitro 27, 1789–1797.

van Staden, C. J., Morgan, R. E., Ramachandran, B., Chen, Y., Lee, P. H., and Hamadeh, H. K. (2012). Membrane vesicle ABC transporter assays for drug safety assessment. Curr. Protoc. Toxicol. Chapter 23, Unit 23.5.

Wang, R., Chen, H. L., Liu, L., Sheps, J. A., Phillips, M. J., and Ling, V. (2009). Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 50, 948–956.

Wang, R., Salem, M., Yousef, I. M., Tuchweber, B., Lam, P., Childs, S. J., Helgason, C. D., Ackerley, C., Phillips, M. J., and Ling, V. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intra-hepatic cholestasis. Proc. Natl. Acad. Sci. U. S. A. 98, 2011–2016.

Washizu, T., Ikenaga, H., Washizu, M., Ishida, T., Tomoda, I., and Kaneko, J. J. (1990). Bile acid composition of dog and cat gall-bladder bile. Nihon Juigaku Zaashi 52, 423–425.

Yang, K., Kock, K., Sedykh, A., Tropsha, A., and Brouwer, K. L. (2013). An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 102, 3037–3057.

Zhang, Y. K., Guo, G. L., and Klaassen, C. D. (2011). Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters. PLoS One 6, e16683.